Cat. #154646
MCF7A estrogen independent breast cancer cell line panel
Cat. #: 154646
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Organism: Human
Tissue: Breast
Disease: Cancer
Model: Cancer Model
£2,070.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Erasmus University Medical Center (Erasmus MC)
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: MCF7A estrogen independent breast cancer cell line panel
- Cancer: Gynaecologic cancer
- Cancers detailed: Estrogen dependent;Mammary adenocarcinoma
- Research fields: Cancer;Drug development
- Tool sub type: Continuous
- Parental cell: MCF7A
- Organism: Human
- Tissue: Breast
- Disease: Cancer
- Model: Cancer Model
- Conditional: No
- Description: Endocrine therapy of breast cancer has been applied widely and proven to be effective. However, in many instances endocrine treatments ultimately fail due to the development of an estrogen-independent therapy resistant phenotype. To elucidate the molecular mechanism underlying this endocrine therapy failure, the laboratory of Lambert Dorssers applied different genetic screens to identify the main genes conferring estrogen independence. Out of 15 candidate BCAR genes, several including BCAR3, BCAR4 and AKT1 were shown to directly underlie estrogen independence to MCF7A breast cancer cells. These genes were transfected into the MCF7A breast cancer cell line resulting in a panel of 4 cell lines (Cat No 154636-154638, 154643). These cell lines are a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression, therapy resistance and to test the effectiveness of novel drugs to combat different modes of anti-estrogen insensitivity
- Production details: Full length cDNA of the relevant gene was introduced in the estrogen-dependant MCF7A cell line by transfection with lipofectamine
Target Details
- Target: BCAR3, BCAR4, AKT1
Applications
- Application notes: The cell lines are also resistant to Geneticin which may be included in the culture to maintain the expression plasmid
Handling
- Format: Frozen
- Growth medium: RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS)
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
References
- Godinho et al. 2011. J Cell Physiol. 226(7):1741-9. PMID: 21506106.
- van Agthoven et al. 2010. Endocr Relat Cancer. 17(1):215-30. PMID: 19966015.
- van Agthoven et al. 1998. EMBO J. 17(10):2799-808. PMID: 9582273.
